The remarkable alteration in FLI1 expression and expressional alterations of fibrosis marker genes (fibronectin and collagen I) in the BSYJ-containing serum-treated group indicated that BSYJ could suppress SSc pathogenesis by modulating the miR-26a-mediated FLI1 gene expression. This evidence concerns the gene FLI1 and systemic sclerosis.